董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Julian Baker | 男 | Director | 58 | 37.23万美元 | 未持股 | 2025-10-30 |
| James Daly | 男 | Director | 63 | 38.23万美元 | 未持股 | 2025-10-30 |
| Edmund Harrigan | 男 | Director | 72 | 38.23万美元 | 未持股 | 2025-10-30 |
| Elizabeth A. Garofalo | 女 | Director | 67 | 37.23万美元 | 未持股 | 2025-10-30 |
| Adora Ndu | 女 | Director | 44 | 32.30万美元 | 未持股 | 2025-10-30 |
| Catherine Owen Adams | 女 | Director and Chief Executive Officer | 54 | 未披露 | 未持股 | 2025-10-30 |
| Stephen R. Biggar | 男 | Chair of the Board and Director | 54 | 42.73万美元 | 未持股 | 2025-10-30 |
| Laura Brege | 女 | Director | 67 | 38.73万美元 | 未持股 | 2025-10-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elizabeth H.Z. Thompson | 女 | Executive Vice President, Head of Research and Development | 50 | 未披露 | 未持股 | 2025-10-30 |
| Mark C. Schneyer | 男 | Executive Vice President and Chief Financial Officer | 51 | 235.32万美元 | 未持股 | 2025-10-30 |
| Thomas Garner | 男 | Executive Vice President and Chief Commercial Officer | 49 | 未披露 | 未持股 | 2025-10-30 |
| Catherine Owen Adams | 女 | Director and Chief Executive Officer | 54 | 未披露 | 未持股 | 2025-10-30 |
| Jennifer J. Rhodes | 女 | Executive Vice President, Chief Legal Officer and Secretary | 55 | 未披露 | 未持股 | 2025-10-30 |
董事简历
中英对照 | 中文 | 英文- Julian Baker
-
Julian Baker自2015年12月起担任Acadia Pharmaceuticals Inc.的董事。Baker先生是Baker Brothers Investments的执行合伙人，负责管理长期投资基金，专注于上市的生命科学公司，主要大学捐赠和基金会。Baker先生和他的弟弟Felix Baker博士于2000年创立了该公司。Baker先生作为基金经理的职业生涯开始于1994年，当时他与Tisch家族共同创立了一个生物技术投资合作伙伴关系。Baker先生目前在Incyte Corporation，Genomic Health，Inc.和Idera Pharmaceuticals，Inc.的董事会任职。Baker先生持有 Harvard University文学士（荣誉）学位。
Julian Baker,has served as a director of the Company since December 2015. Mr. Baker is a Managing Member of Baker Bros. Advisors LP ("Baker Bros."), a registered investment adviser focused on long-term investments in life-sciences companies. Mr. Baker founded Baker Bros. in 2000, together with his brother, Felix Baker, Ph.D. Prior to founding Baker Bros., Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker currently serves on the boards of directors of Incyte Corporation, Madrigal Pharmaceuticals, Inc., and Prelude Therapeutics Inc., each public companies. Mr. Baker also serves as a member or observer on the boards of directors of several privately held biotechnology companies. - Julian Baker自2015年12月起担任Acadia Pharmaceuticals Inc.的董事。Baker先生是Baker Brothers Investments的执行合伙人，负责管理长期投资基金，专注于上市的生命科学公司，主要大学捐赠和基金会。Baker先生和他的弟弟Felix Baker博士于2000年创立了该公司。Baker先生作为基金经理的职业生涯开始于1994年，当时他与Tisch家族共同创立了一个生物技术投资合作伙伴关系。Baker先生目前在Incyte Corporation，Genomic Health，Inc.和Idera Pharmaceuticals，Inc.的董事会任职。Baker先生持有 Harvard University文学士（荣誉）学位。
- Julian Baker,has served as a director of the Company since December 2015. Mr. Baker is a Managing Member of Baker Bros. Advisors LP ("Baker Bros."), a registered investment adviser focused on long-term investments in life-sciences companies. Mr. Baker founded Baker Bros. in 2000, together with his brother, Felix Baker, Ph.D. Prior to founding Baker Bros., Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker currently serves on the boards of directors of Incyte Corporation, Madrigal Pharmaceuticals, Inc., and Prelude Therapeutics Inc., each public companies. Mr. Baker also serves as a member or observer on the boards of directors of several privately held biotechnology companies.
- James Daly
-
James Daly自2016年1月起担任公司的董事。Daly先生2012年10月至2015年6月曾担任 Incyte Corporation的执行副总裁兼首席商务官。在他任职期间，他在重新加速推出Jakafi和推动持续增长。在加入Incyte之前，Daly 先生在Amgen, Inc.任职10年，持有多个领导职务。在他最后的职务里，Daly 先生担任北美商业运营、全球营销和商业开发的高级副总裁。此前，他曾担任Amgen&’s Oncology Business Unit的副总裁兼总经理。他在Amgen的球队负责成功推出许多产品，包括Aranesp, Neulasta, Vectibix, Nplate, Xgeva 和 Prolia。此前，Daly先生在Glaxo Wellcome/GlaxoSmithKline GSK任职16年，在那里他担任越来越重要的职务，包括Respiratory and Anti-Infective Business Unit的高级副总裁、总经理，带领美国Advair的推出。他目前任职Chimerix Inc.（一家上市公司）的董事会。Daly 先生获得了University at Buffalo, The State University of New York药剂业的学士学位和工商管理硕士学位。
James Daly,has served as a director of the Company since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen's Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp, Neulasta, Vectibix, Nplate, Xgeva and Prolia. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair. Mr. Daly currently serves on the boards of directors of Argenx SE and Madrigal Pharmaceuticals, Inc., each public companies. During the past five years, Mr. Daly has served on the boards of directors of Chimerix Inc., Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. Mr. Daly earned his B.S. in pharmacy and M.B.A. from the University at Buffalo, The State University of New York. - James Daly自2016年1月起担任公司的董事。Daly先生2012年10月至2015年6月曾担任 Incyte Corporation的执行副总裁兼首席商务官。在他任职期间，他在重新加速推出Jakafi和推动持续增长。在加入Incyte之前，Daly 先生在Amgen, Inc.任职10年，持有多个领导职务。在他最后的职务里，Daly 先生担任北美商业运营、全球营销和商业开发的高级副总裁。此前，他曾担任Amgen&’s Oncology Business Unit的副总裁兼总经理。他在Amgen的球队负责成功推出许多产品，包括Aranesp, Neulasta, Vectibix, Nplate, Xgeva 和 Prolia。此前，Daly先生在Glaxo Wellcome/GlaxoSmithKline GSK任职16年，在那里他担任越来越重要的职务，包括Respiratory and Anti-Infective Business Unit的高级副总裁、总经理，带领美国Advair的推出。他目前任职Chimerix Inc.（一家上市公司）的董事会。Daly 先生获得了University at Buffalo, The State University of New York药剂业的学士学位和工商管理硕士学位。
- James Daly,has served as a director of the Company since January 2016. Mr. Daly served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from October 2012 to June 2015. Prior to joining Incyte, Mr. Daly worked for Amgen, Inc. for 10 years, holding multiple leadership positions, including Senior Vice President, North America Commercial Operations, Global Marketing and Commercial Development. Previously, he served as Vice President and General Manager of Amgen's Oncology Business Unit. His teams at Amgen were responsible for the successful launch of many products, including Aranesp, Neulasta, Vectibix, Nplate, Xgeva and Prolia. Previously, Mr. Daly spent over 16 years with Glaxo Wellcome/GlaxoSmithKline, where he held roles of increasing responsibility, including Senior Vice President, General Manager, Respiratory and Anti-Infective Business Unit, and led the U.S. launch of Advair. Mr. Daly currently serves on the boards of directors of Argenx SE and Madrigal Pharmaceuticals, Inc., each public companies. During the past five years, Mr. Daly has served on the boards of directors of Chimerix Inc., Bellicum Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. Mr. Daly earned his B.S. in pharmacy and M.B.A. from the University at Buffalo, The State University of New York.
- Edmund Harrigan
-
Edmund Harrigan，他是Acadia Pharmaceuticals Inc.的董事（2015年11月以来）。他曾担任Pfizer Inc的高级副总裁，负责全球安全和监管（2012年至2015年），在那里他曾领导80个国家的3500人的团队，该团队负责收集、解释和报告600多个销售产品的临床安全数据，以及监管全球卫生机构。他此前曾担任Pfizer公司的执行领导职务，包括担任高级副总裁、全球商业开发主管、高级副总裁、全球监管事务和质量保证主管、副总裁、神经科学和眼科主管。职业生涯早期，他曾任职Pfizer公司，担任临床研究副总裁、治疗区域负责人，涉及中枢神经系统和疼痛。1990年进入医药行业之前，他曾担任实践神经学家7年。他目前任职于Karuna Pharmaceuticals Inc的董事会。他持有St. Anselm College的化学学士学位，以及Massachusetts大学（位于伍斯特）的医学博士学位。他也曾就读于California大学洛杉矶分校的大脑研究所。
Edmund Harrigan,has served as a director of the Company since November 2015. Since July 2015, Dr. Harrigan has served as Principal at Harrigan Consulting, LLC, a consulting firm providing business consulting services to life sciences companies. Previously, Dr. Harrigan served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan's previous executive leadership roles at Pfizer included serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the boards of directors of Incyte Corp., a public company, and Modulo Inc., a privately-held company. During the past five years, Dr. Harrigan has served on the boards of directors of PhaseBio Pharmaceuticals, Inc., Bellicum Pharmaceuticals, Inc. and Karuna Therapeutics, Inc. Dr. Harrigan earned his B.A. in chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester. - Edmund Harrigan，他是Acadia Pharmaceuticals Inc.的董事（2015年11月以来）。他曾担任Pfizer Inc的高级副总裁，负责全球安全和监管（2012年至2015年），在那里他曾领导80个国家的3500人的团队，该团队负责收集、解释和报告600多个销售产品的临床安全数据，以及监管全球卫生机构。他此前曾担任Pfizer公司的执行领导职务，包括担任高级副总裁、全球商业开发主管、高级副总裁、全球监管事务和质量保证主管、副总裁、神经科学和眼科主管。职业生涯早期，他曾任职Pfizer公司，担任临床研究副总裁、治疗区域负责人，涉及中枢神经系统和疼痛。1990年进入医药行业之前，他曾担任实践神经学家7年。他目前任职于Karuna Pharmaceuticals Inc的董事会。他持有St. Anselm College的化学学士学位，以及Massachusetts大学（位于伍斯特）的医学博士学位。他也曾就读于California大学洛杉矶分校的大脑研究所。
- Edmund Harrigan,has served as a director of the Company since November 2015. Since July 2015, Dr. Harrigan has served as Principal at Harrigan Consulting, LLC, a consulting firm providing business consulting services to life sciences companies. Previously, Dr. Harrigan served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan's previous executive leadership roles at Pfizer included serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain. Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves on the boards of directors of Incyte Corp., a public company, and Modulo Inc., a privately-held company. During the past five years, Dr. Harrigan has served on the boards of directors of PhaseBio Pharmaceuticals, Inc., Bellicum Pharmaceuticals, Inc. and Karuna Therapeutics, Inc. Dr. Harrigan earned his B.A. in chemistry from St. Anselm College and holds an M.D. from the University of Massachusetts at Worcester.
- Elizabeth A. Garofalo
-
Elizabeth A. Garofalo，自2020年9月起担任公司董事。自2016年以来，Garofalo博士一直担任EAG Pharma Consulting LLC的负责人。在此之前，Garofalo博士曾在诺华国际集团担任过多个领导职务，包括担任高级副总裁兼临床开发全球主管、诺华全球开发领导团队成员、诺华投资组合管理委员会主席和诺华神经科学专营权联席主管。在任职于诺华公司之前，Garofalo博士是Astellas Pharma，Inc.的副总裁兼神经科学治疗领域负责人。Garofalo博士的职业生涯始于Parke-Davis/辉瑞，在那里她担任的职务越来越重要，包括Ann Arbor Site神经科学负责人和Ann Arbor Site全球监管事务负责人。Garofalo博士目前在Exicure, Inc.、Alector，Inc.和Xenon Pharmaceuticals Inc.的董事会任职。她还担任儿童高级临床试验研究所的董事会成员，并且是美国癫痫基金会商业顾问委员会的主席。加罗法洛博士在印第安纳大学医学院获得医学博士学位，在那里她完成了儿科住院医师实习。她在密歇根大学医学院完成了小儿神经病学和癫痫方面的研究金。
Elizabeth A. Garofalo,has served as a director of the Company since September 2020. Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leadership roles at Novartis International AG, including as Senior Vice President and Global Head of Clinical Development and member of the Novartis Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board and Co-Head of the Novartis Neuroscience Franchise. Prior to serving at Novartis, Dr. Garofalo was Vice President and Head of the Neuroscience Therapy Area at Astellas Pharma, Inc. Dr. Garofalo started her career at Parke-Davis/Pfizer, where she held positions of increasing responsibility including Ann Arbor Site Head of Neuroscience and Ann Arbor Site Head of Worldwide Regulatory Affairs. Dr. Garofalo currently serves on the boards of directors of Alector, Inc. and Xenon Pharmaceuticals Inc., each public companies. During the past five years, Dr. Garofalo served on the board of directors of Exicure Inc. She also chairs the board of the Institute for Advanced Clinical Trials for Children and was the Chair of the Business Advisory Board for the Epilepsy Foundation of America. Dr. Garofalo earned her M.D. from the Indiana University School of Medicine where she completed her pediatric residency. She completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School. - Elizabeth A. Garofalo，自2020年9月起担任公司董事。自2016年以来，Garofalo博士一直担任EAG Pharma Consulting LLC的负责人。在此之前，Garofalo博士曾在诺华国际集团担任过多个领导职务，包括担任高级副总裁兼临床开发全球主管、诺华全球开发领导团队成员、诺华投资组合管理委员会主席和诺华神经科学专营权联席主管。在任职于诺华公司之前，Garofalo博士是Astellas Pharma，Inc.的副总裁兼神经科学治疗领域负责人。Garofalo博士的职业生涯始于Parke-Davis/辉瑞，在那里她担任的职务越来越重要，包括Ann Arbor Site神经科学负责人和Ann Arbor Site全球监管事务负责人。Garofalo博士目前在Exicure, Inc.、Alector，Inc.和Xenon Pharmaceuticals Inc.的董事会任职。她还担任儿童高级临床试验研究所的董事会成员，并且是美国癫痫基金会商业顾问委员会的主席。加罗法洛博士在印第安纳大学医学院获得医学博士学位，在那里她完成了儿科住院医师实习。她在密歇根大学医学院完成了小儿神经病学和癫痫方面的研究金。
- Elizabeth A. Garofalo,has served as a director of the Company since September 2020. Since 2016, Dr. Garofalo has served as the Principal for EAG Pharma Consulting LLC. Prior to that, Dr. Garofalo served in numerous leadership roles at Novartis International AG, including as Senior Vice President and Global Head of Clinical Development and member of the Novartis Global Development Leadership Team, Chair of the Novartis Portfolio Stewardship Board and Co-Head of the Novartis Neuroscience Franchise. Prior to serving at Novartis, Dr. Garofalo was Vice President and Head of the Neuroscience Therapy Area at Astellas Pharma, Inc. Dr. Garofalo started her career at Parke-Davis/Pfizer, where she held positions of increasing responsibility including Ann Arbor Site Head of Neuroscience and Ann Arbor Site Head of Worldwide Regulatory Affairs. Dr. Garofalo currently serves on the boards of directors of Alector, Inc. and Xenon Pharmaceuticals Inc., each public companies. During the past five years, Dr. Garofalo served on the board of directors of Exicure Inc. She also chairs the board of the Institute for Advanced Clinical Trials for Children and was the Chair of the Business Advisory Board for the Epilepsy Foundation of America. Dr. Garofalo earned her M.D. from the Indiana University School of Medicine where she completed her pediatric residency. She completed fellowships in pediatric neurology and epilepsy at the University of Michigan Medical School.
- Adora Ndu
-
Adora Ndu，自2022年10月起担任公司董事。Ndu博士自2022年1月起担任BridgeBio Pharma Inc.的首席监管事务官，自2022年10月起担任BridgeBio的首席监管和临时法律官。自2019年以来，Ndu博士还担任约翰霍普金斯大学的兼职教员。在加入BridgeBio Pharma之前，Ndu博士于2021年1月至2022年1月在BioMarin Pharmaceutical，Inc.担任集团副总裁，负责全球研发、战略、科学合作和政策。她此前曾在BioMarin担任越来越重要的职务，包括2019年3月至2020年12月担任监管事务、政策、研究、参与和国际副总裁，2017年9月至2019年3月担任监管事务执行董事，2017年2月至2017年9月担任高级董事。Ndu博士还在2016年至2019年期间担任马里兰大学大学学院的兼职教员，并在2008年至2016年期间担任美国食品和药物管理局的各种职务，最近担任医疗政策制定司的司司长。Ndu博士目前担任DVB Technologies S.A.的董事会成员。Ndu博士在霍华德大学获得药学博士学位，在马里兰大学Francis King Carey法学院获得法学博士学位。
Adora Ndu,has served as a director of the Company since October 2022. Dr. Ndu has served as Chief Regulatory Affairs Officer of BridgeBio Pharma Inc. since January 2022, as Chief Regulatory and Interim Legal Officer at BridgeBio Pharma from October 2022 to September 2023, and as Chief Regulatory Officer & Executive Vice President of Portfolio Strategy and Management since October 2024. Dr. Ndu has also served as an adjunct faculty member at Johns Hopkins University since 2019. Prior to joining BridgeBio Pharma, Dr. Ndu served as Group Vice President, Worldwide Research & Development, Strategy, Scientific Collaborations and Policy at BioMarin Pharmaceutical Inc. from January 2021 to January 2022. She previously served in positions of increasing responsibility at BioMarin, including as Vice President, Regulatory Affairs, Policy, Research, Engagement & International from March 2019 to December 2020, Executive Director, Regulatory Affairs from September 2017 to March 2019 and Senior Director from February 2017 to September 2017. Dr. Ndu also served as an adjunct faculty member at the University of Maryland University College from 2016 to 2019, and in various roles at the U.S. Food and Drug Administration from 2008 to 2016, most recently as a Division Director in the Division of Medical Policy Development. Dr. Ndu currently serves on the board of directors of DBV Technologies S.A., a public company. Dr. Ndu earned her Pharm.D. from Howard University and her J.D. from the University of Maryland Francis King Carey School of Law. - Adora Ndu，自2022年10月起担任公司董事。Ndu博士自2022年1月起担任BridgeBio Pharma Inc.的首席监管事务官，自2022年10月起担任BridgeBio的首席监管和临时法律官。自2019年以来，Ndu博士还担任约翰霍普金斯大学的兼职教员。在加入BridgeBio Pharma之前，Ndu博士于2021年1月至2022年1月在BioMarin Pharmaceutical，Inc.担任集团副总裁，负责全球研发、战略、科学合作和政策。她此前曾在BioMarin担任越来越重要的职务，包括2019年3月至2020年12月担任监管事务、政策、研究、参与和国际副总裁，2017年9月至2019年3月担任监管事务执行董事，2017年2月至2017年9月担任高级董事。Ndu博士还在2016年至2019年期间担任马里兰大学大学学院的兼职教员，并在2008年至2016年期间担任美国食品和药物管理局的各种职务，最近担任医疗政策制定司的司司长。Ndu博士目前担任DVB Technologies S.A.的董事会成员。Ndu博士在霍华德大学获得药学博士学位，在马里兰大学Francis King Carey法学院获得法学博士学位。
- Adora Ndu,has served as a director of the Company since October 2022. Dr. Ndu has served as Chief Regulatory Affairs Officer of BridgeBio Pharma Inc. since January 2022, as Chief Regulatory and Interim Legal Officer at BridgeBio Pharma from October 2022 to September 2023, and as Chief Regulatory Officer & Executive Vice President of Portfolio Strategy and Management since October 2024. Dr. Ndu has also served as an adjunct faculty member at Johns Hopkins University since 2019. Prior to joining BridgeBio Pharma, Dr. Ndu served as Group Vice President, Worldwide Research & Development, Strategy, Scientific Collaborations and Policy at BioMarin Pharmaceutical Inc. from January 2021 to January 2022. She previously served in positions of increasing responsibility at BioMarin, including as Vice President, Regulatory Affairs, Policy, Research, Engagement & International from March 2019 to December 2020, Executive Director, Regulatory Affairs from September 2017 to March 2019 and Senior Director from February 2017 to September 2017. Dr. Ndu also served as an adjunct faculty member at the University of Maryland University College from 2016 to 2019, and in various roles at the U.S. Food and Drug Administration from 2008 to 2016, most recently as a Division Director in the Division of Medical Policy Development. Dr. Ndu currently serves on the board of directors of DBV Technologies S.A., a public company. Dr. Ndu earned her Pharm.D. from Howard University and her J.D. from the University of Maryland Francis King Carey School of Law.
- Catherine Owen Adams
-
Catherine Owen Adams，自2024年9月起担任首席执行官和董事会成员。此前，Owen Adams女士曾在全球生物制药公司Bristol Myers Squibb Company（“BMS”）担任高级副总裁兼美国区总经理，在那里她领导了一项价值200亿美元的商业业务，从2019年9月到2024年4月，她负责监督肿瘤学、心血管学和免疫学领域的大量多元化推广品牌组合。在这个角色中，她领导了超过3000名员工，并在肺癌、阻塞性肥厚型心肌病和银屑病领域推出了主要产品。在此之前，欧文·亚当斯女士曾担任BMS高级副总裁兼主要市场主管，在BMS与Celgene合并期间，她领导了商业运营，在欧洲、日本和加拿大的19个国家领导着6,000名员工。在她的领导下，她的团队在肿瘤学、CAR-T、血液学和免疫学领域实现了9个新产品发布，进一步巩固了她作为制药领域全球领导者的声誉。在任职于BMS之前，Owen Adams女士在强生（“强生”）工作了25年，在那里她在全球、美国和欧洲的业务部门担任领导职务，最后一个职位是杨森免疫学美国公司总裁。在强生的职业生涯中，她在制药和医疗技术领域的营销、销售、市场准入、研发以及内部企业方面积累了深厚的经验。目前，Owen Adams女士在公众持股公司Agios制药公司和私人持股公司AssistRX的董事会任职。Owen Adams女士以前是Optinose PLC的董事会成员和薪酬委员会主席，Optinose PLC是一家公共专业制药公司，并且是非营利组织Robert Wood Johnson University Hospitals的董事会成员。Owen Adams女士在获得曼彻斯特大学药学学士学位后，在阿斯利康开始了她的研发和制造职业生涯，成为一名合格的药剂师和皇家药学会（MRPHS）成员。
Catherine Owen Adams,has served as Chief Executive Officer and as a member of Board of Directors since September 2024. Previously, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb Company ("BMS"), a global biopharmaceutical company, where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology from September 2019 to April 2024. In this role, she led over 3,000 employees and major product launches in lung cancer, obstructive hypertrophic cardiomyopathy, and psoriasis. Before this, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Under her leadership her teams achieved 9 new product launches in Oncology, CAR-T, Hematology, and Immunology, further solidifying her reputation as a global leader in the pharmaceutical space. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson ("J&J"), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Over her career at J&J, she gained deep experience in marketing, sales, market access, R&D, and internal ventures across both the Pharmaceutical and Medical Technology sectors. Currently, Ms. Owen Adams serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca after earning a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS). - Catherine Owen Adams，自2024年9月起担任首席执行官和董事会成员。此前，Owen Adams女士曾在全球生物制药公司Bristol Myers Squibb Company（“BMS”）担任高级副总裁兼美国区总经理，在那里她领导了一项价值200亿美元的商业业务，从2019年9月到2024年4月，她负责监督肿瘤学、心血管学和免疫学领域的大量多元化推广品牌组合。在这个角色中，她领导了超过3000名员工，并在肺癌、阻塞性肥厚型心肌病和银屑病领域推出了主要产品。在此之前，欧文·亚当斯女士曾担任BMS高级副总裁兼主要市场主管，在BMS与Celgene合并期间，她领导了商业运营，在欧洲、日本和加拿大的19个国家领导着6,000名员工。在她的领导下，她的团队在肿瘤学、CAR-T、血液学和免疫学领域实现了9个新产品发布，进一步巩固了她作为制药领域全球领导者的声誉。在任职于BMS之前，Owen Adams女士在强生（“强生”）工作了25年，在那里她在全球、美国和欧洲的业务部门担任领导职务，最后一个职位是杨森免疫学美国公司总裁。在强生的职业生涯中，她在制药和医疗技术领域的营销、销售、市场准入、研发以及内部企业方面积累了深厚的经验。目前，Owen Adams女士在公众持股公司Agios制药公司和私人持股公司AssistRX的董事会任职。Owen Adams女士以前是Optinose PLC的董事会成员和薪酬委员会主席，Optinose PLC是一家公共专业制药公司，并且是非营利组织Robert Wood Johnson University Hospitals的董事会成员。Owen Adams女士在获得曼彻斯特大学药学学士学位后，在阿斯利康开始了她的研发和制造职业生涯，成为一名合格的药剂师和皇家药学会（MRPHS）成员。
- Catherine Owen Adams,has served as Chief Executive Officer and as a member of Board of Directors since September 2024. Previously, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb Company ("BMS"), a global biopharmaceutical company, where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology from September 2019 to April 2024. In this role, she led over 3,000 employees and major product launches in lung cancer, obstructive hypertrophic cardiomyopathy, and psoriasis. Before this, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Under her leadership her teams achieved 9 new product launches in Oncology, CAR-T, Hematology, and Immunology, further solidifying her reputation as a global leader in the pharmaceutical space. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson ("J&J"), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Over her career at J&J, she gained deep experience in marketing, sales, market access, R&D, and internal ventures across both the Pharmaceutical and Medical Technology sectors. Currently, Ms. Owen Adams serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca after earning a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).
- Stephen R. Biggar
-
Stephen R. Biggar，自2015年10月起担任Kiniksa Pharmaceuticals, Ltd.的董事会成员。自从公司合并以来，他担任Acadia Pharmaceuticals Inc.董事，在那之前，自2004年5月以来，他担任Private Synageva的董事。2006年10月以来，Biggar博士担任一家专门从事对生命科学公司长期投资的注册投资顾问公司Baker Bros. Advisors LP的合伙人。Biggar博士2000年加入Baker Bros. Advisors LP。在加入Baker Bros之前，Biggar博士拥有斯坦福大学医学博士和免疫学博士，以及罗切斯特大学遗传学学士学位。Biggar博士也担任一家上市生物科学贸易公司ACADIA Pharmaceuticals的董事。
Stephen R. Biggar,has served as a director of the Company since January 2013, and as chairman of Acadia Pharmaceuticals Inc. board of directors since June 2016. Dr. Biggar currently serves as Partner at Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. Dr. Biggar joined Baker Bros. Advisors LP in 2000. Dr. Biggar currently serves on the boards of directors of Kiniksa Pharmaceuticals, Ltd. and TScan Therapeutics, Inc., each public companies. Dr. Biggar also serves on the board of directors of Notch Therapeutics, Inc., a private company, and the University of Rochester Board of Trustees. During the past five years, Mr. Biggar has served on the board of directors of Vivelix Pharmaceuticals Corp. and Neurogene, Inc. Dr. Biggar received an M.D. and a Ph.D. in immunology from Stanford University and received a B.S. in genetics from the University of Rochester. - Stephen R. Biggar，自2015年10月起担任Kiniksa Pharmaceuticals, Ltd.的董事会成员。自从公司合并以来，他担任Acadia Pharmaceuticals Inc.董事，在那之前，自2004年5月以来，他担任Private Synageva的董事。2006年10月以来，Biggar博士担任一家专门从事对生命科学公司长期投资的注册投资顾问公司Baker Bros. Advisors LP的合伙人。Biggar博士2000年加入Baker Bros. Advisors LP。在加入Baker Bros之前，Biggar博士拥有斯坦福大学医学博士和免疫学博士，以及罗切斯特大学遗传学学士学位。Biggar博士也担任一家上市生物科学贸易公司ACADIA Pharmaceuticals的董事。
- Stephen R. Biggar,has served as a director of the Company since January 2013, and as chairman of Acadia Pharmaceuticals Inc. board of directors since June 2016. Dr. Biggar currently serves as Partner at Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life-sciences companies. Dr. Biggar joined Baker Bros. Advisors LP in 2000. Dr. Biggar currently serves on the boards of directors of Kiniksa Pharmaceuticals, Ltd. and TScan Therapeutics, Inc., each public companies. Dr. Biggar also serves on the board of directors of Notch Therapeutics, Inc., a private company, and the University of Rochester Board of Trustees. During the past five years, Mr. Biggar has served on the board of directors of Vivelix Pharmaceuticals Corp. and Neurogene, Inc. Dr. Biggar received an M.D. and a Ph.D. in immunology from Stanford University and received a B.S. in genetics from the University of Rochester.
- Laura Brege
-
Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大工商管理硕士学位。
Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. - Laura Brege，2012年7月她获委任为董事，现任Nodality的总裁兼首席执行官，这是一家私人持有的生物技术公司，专注于提高癌症和自身免疫性疾病的治疗学的发展和临床应用。她担任阿卡迪亚制药公司、Pacira制药公司和Aratana Therapeutics公司的董事会成员，并是BayBio的董事会成员，这是北加州的一家服务于生命科学产业的独立的、非营利性的行业协会。她拥有超过20年的制药、生物技术和风险投资行业的行政管理经验。在加入Nodality之前，她在Onyx制药公司担任多个高级职位，包括执行副总裁兼首席运营官。而在Onyx，她带领多项功能，其中包括商业化、战略规划、企业发展以及医疗、科研和政府事务。在Onyx之前，她是红岩资本管理的一位普通合伙，这是一家风险投资公司，专注于科技公司的早期融资。此前她是COR治疗的高级副总裁兼首席财务官，有助于通过商业发射成功的心血管产品从早期研发公司建立公司。在她的职业生涯早期，她曾担任 Flextronics公司的首席财务官和库珀公司的财务总监。她获得了俄亥俄大学荣誉教学学院经济学和政治学的本科学位；和芝加哥大工商管理硕士学位。
- Laura Brege,has served as a director of the Company since May 2008. Since April 2017, Ms. Brege has served as a Senior Advisor to BridgeBio Pharma, Inc. From September 2015 to December 2017, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a consulting firm providing integrated business solutions to life sciences companies. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 to 2012, including Executive Vice President and Chief Operating Officer. While at Onyx, Ms. Brege led multiple functions, including commercialization, strategic planning, corporate development and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Previously, Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc., where she helped build the company from an early-stage research and development company through commercial launch of a successful cardiovascular product. Earlier in her career, Ms. Brege served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege currently serves on the boards of directors of Edgewise Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Pacira BioSciences, Inc., each public companies, and T-knife Therapeutics, Inc., a privately held company. During the past five years, Ms. Brege has served on the boards of directors of Aratana Therapeutics, Inc., California Life Sciences Association, Dynavax Technologies Corporation, HLS Therapeutics, Inc. and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Elizabeth H.Z. Thompson
Elizabeth H.Z. Thompson，自2021年3月起担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发。她曾于2020年1月至2021年3月担任Horizon Therapeutics Public Limited Company集团副总裁，负责开发和外部搜索，并于2018年6月至2020年1月担任Horizon Therapeutics Public Limited Company副总裁，负责临床开发（罕见病）。在加入Horizon之前，她于2017年4月至2018年5月在艾伯维担任临床开发团队科学总监，并于2015年9月至2017年4月担任临床开发高级科学总监。在艾伯维任职期间，她是risankizumab（SKYRIZI）的临床负责人，支持全球提交和批准。在加入艾伯维之前，汤普森博士曾在Raptor、InterMune和安进任职，职业生涯涵盖临床开发、商业发展和医疗交流。汤普森博士在哈维穆德学院获得化学理学士学位，在斯克里普斯研究所获得大分子和细胞结构及化学博士学位。
Elizabeth H.Z. Thompson,has served as Horizon Therapeutics Public Limited Company executive vice president, research and development since March 2021. Previously she served as Horizon Therapeutics Public Limited Company group vice president, development and external search from January 2020 to March 2021, and as Horizon Therapeutics Public Limited Company vice president, clinical development (rare disease) from June 2018 to January 2020. Prior to joining Horizon, she was with AbbVie as group scientific director, clinical development from April 2017 to May 2018 and senior scientific director, clinical development, from September 2015 to April 2017. While at AbbVie, she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson received a bachelor of science degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from The Scripps Research Institute.- Elizabeth H.Z. Thompson，自2021年3月起担任Horizon Therapeutics Public Limited Company执行副总裁，负责研发。她曾于2020年1月至2021年3月担任Horizon Therapeutics Public Limited Company集团副总裁，负责开发和外部搜索，并于2018年6月至2020年1月担任Horizon Therapeutics Public Limited Company副总裁，负责临床开发（罕见病）。在加入Horizon之前，她于2017年4月至2018年5月在艾伯维担任临床开发团队科学总监，并于2015年9月至2017年4月担任临床开发高级科学总监。在艾伯维任职期间，她是risankizumab（SKYRIZI）的临床负责人，支持全球提交和批准。在加入艾伯维之前，汤普森博士曾在Raptor、InterMune和安进任职，职业生涯涵盖临床开发、商业发展和医疗交流。汤普森博士在哈维穆德学院获得化学理学士学位，在斯克里普斯研究所获得大分子和细胞结构及化学博士学位。
- Elizabeth H.Z. Thompson,has served as Horizon Therapeutics Public Limited Company executive vice president, research and development since March 2021. Previously she served as Horizon Therapeutics Public Limited Company group vice president, development and external search from January 2020 to March 2021, and as Horizon Therapeutics Public Limited Company vice president, clinical development (rare disease) from June 2018 to January 2020. Prior to joining Horizon, she was with AbbVie as group scientific director, clinical development from April 2017 to May 2018 and senior scientific director, clinical development, from September 2015 to April 2017. While at AbbVie, she was the clinical lead for risankizumab (SKYRIZI), supporting global submissions and approvals. Before AbbVie, Dr. Thompson held roles at Raptor, InterMune and Amgen in a career spanning clinical development, business development and medical communications. Dr. Thompson received a bachelor of science degree in chemistry from Harvey Mudd College and a doctorate in macromolecular and cellular structure and chemistry from The Scripps Research Institute.
- Mark C. Schneyer
Mark C. Schneyer，自2021年12月起担任Acadia Pharmaceuticals Inc.执行副总裁兼首席财务官。Schneyer先生于2020年5月加入公司，担任高级副总裁、业务发展和首席商务官。2021年9月至2021年12月担任公司临时首席财务官。Schneyer先生于2019年至2020年5月从辉瑞公司加入公司，最近担任Upjohn部门业务发展副总裁。Schneyer先生于2011年加入辉瑞的全球业务发展组织，曾担任过各种责任越来越大的业务发展职位，监督涵盖许可协议、产品收购和资产剥离、战略合作和公司收购的战略交易。在任职于辉瑞之前，Schneyer先生是Lazard的一名投资银行家，在该公司为医疗保健部门的董事会和高级管理团队提供建议。Schneyer先生获得了宾夕法尼亚大学沃顿商学院金融专业的经济学理学学士学位。
Mark C. Schneyer,has served as Executive Vice President and Chief Financial Officer since December 2021. Mr. Schneyer joined the Company in May 2020 as Senior Vice President, Business Development and Chief Business Officer. From September 2021 to December 2021, he served as the Company's Interim Chief Financial Officer. Mr. Schneyer joined the Company from Pfizer Inc., a publicly traded pharmaceutical company, where he was most recently Vice President, Business Development for the Upjohn division, from 2019 to May 2020. Mr. Schneyer joined Pfizer's Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility. Prior to serving at Pfizer, Mr. Schneyer was an investment banker at Lazard, a financial advisory and asset management firm from 1996 to 2010. Mr. Schneyer earned his B.S. in economics with a concentration in finance from the Wharton School of the University of Pennsylvania.- Mark C. Schneyer，自2021年12月起担任Acadia Pharmaceuticals Inc.执行副总裁兼首席财务官。Schneyer先生于2020年5月加入公司，担任高级副总裁、业务发展和首席商务官。2021年9月至2021年12月担任公司临时首席财务官。Schneyer先生于2019年至2020年5月从辉瑞公司加入公司，最近担任Upjohn部门业务发展副总裁。Schneyer先生于2011年加入辉瑞的全球业务发展组织，曾担任过各种责任越来越大的业务发展职位，监督涵盖许可协议、产品收购和资产剥离、战略合作和公司收购的战略交易。在任职于辉瑞之前，Schneyer先生是Lazard的一名投资银行家，在该公司为医疗保健部门的董事会和高级管理团队提供建议。Schneyer先生获得了宾夕法尼亚大学沃顿商学院金融专业的经济学理学学士学位。
- Mark C. Schneyer,has served as Executive Vice President and Chief Financial Officer since December 2021. Mr. Schneyer joined the Company in May 2020 as Senior Vice President, Business Development and Chief Business Officer. From September 2021 to December 2021, he served as the Company's Interim Chief Financial Officer. Mr. Schneyer joined the Company from Pfizer Inc., a publicly traded pharmaceutical company, where he was most recently Vice President, Business Development for the Upjohn division, from 2019 to May 2020. Mr. Schneyer joined Pfizer's Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility. Prior to serving at Pfizer, Mr. Schneyer was an investment banker at Lazard, a financial advisory and asset management firm from 1996 to 2010. Mr. Schneyer earned his B.S. in economics with a concentration in finance from the Wharton School of the University of Pennsylvania.
- Thomas Garner
Thomas Garner，自2024年12月起担任执行副总裁兼首席商务官。在加入Acadia之前，Garner先生自2023年10月起担任莱斯康制药公司高级副总裁兼首席商务官。Garner先生此前还曾在BMS担任过一系列商业领导职务，在多个品牌和治疗领域的地方、国家和全球层面工作了20多年，之后加入BMS的Acadia Pharmaceuticals Inc.。他最近于2022年8月至2023年10月担任高级副总裁兼美国心血管和老牌品牌事业部负责人，并于2020年11月至2022年8月担任Camzyos（mavacamten）的副总裁兼美国品牌负责人。在加入BMS之前，Garner先生曾在礼来和公司以及勃林格殷格翰担任过各种资历不断增加的商业职务。Garner先生拥有英国皇家农业大学的理学学士（荣誉）学位和法国INSEAD的一般管理认证。
Thomas Garner,has served as Executive Vice President and Chief Commercial Officer since December 2024. Prior to joining Acadia, Mr. Garner was Senior Vice President and Chief Commercial Officer at Lexicon Pharmaceuticals, Inc. since October 2023. Mr. Garner also previously served in a series of commercial leadership positions at BMS, where he worked for more than 20 years at local, country and global levels across multiple brands and therapeutic areas before joining Acadia Pharmaceuticals Inc. At BMS, he most recently served as senior vice president and head of the U.S. cardiovascular and established brand business unit from August 2022 to October 2023 and as vice president and U.S. brand lead for Camzyos (mavacamten) from November 2020 to August 2022. Prior to joining BMS, Mr. Garner served in various commercial roles of increasing seniority with Eli Lilly and Company, and Boehringer Ingelheim. Mr. Garner holds a BSc (Honors) degree from the Royal Agricultural University in the United Kingdom and a certification in General Management from INSEAD in France.- Thomas Garner，自2024年12月起担任执行副总裁兼首席商务官。在加入Acadia之前，Garner先生自2023年10月起担任莱斯康制药公司高级副总裁兼首席商务官。Garner先生此前还曾在BMS担任过一系列商业领导职务，在多个品牌和治疗领域的地方、国家和全球层面工作了20多年，之后加入BMS的Acadia Pharmaceuticals Inc.。他最近于2022年8月至2023年10月担任高级副总裁兼美国心血管和老牌品牌事业部负责人，并于2020年11月至2022年8月担任Camzyos（mavacamten）的副总裁兼美国品牌负责人。在加入BMS之前，Garner先生曾在礼来和公司以及勃林格殷格翰担任过各种资历不断增加的商业职务。Garner先生拥有英国皇家农业大学的理学学士（荣誉）学位和法国INSEAD的一般管理认证。
- Thomas Garner,has served as Executive Vice President and Chief Commercial Officer since December 2024. Prior to joining Acadia, Mr. Garner was Senior Vice President and Chief Commercial Officer at Lexicon Pharmaceuticals, Inc. since October 2023. Mr. Garner also previously served in a series of commercial leadership positions at BMS, where he worked for more than 20 years at local, country and global levels across multiple brands and therapeutic areas before joining Acadia Pharmaceuticals Inc. At BMS, he most recently served as senior vice president and head of the U.S. cardiovascular and established brand business unit from August 2022 to October 2023 and as vice president and U.S. brand lead for Camzyos (mavacamten) from November 2020 to August 2022. Prior to joining BMS, Mr. Garner served in various commercial roles of increasing seniority with Eli Lilly and Company, and Boehringer Ingelheim. Mr. Garner holds a BSc (Honors) degree from the Royal Agricultural University in the United Kingdom and a certification in General Management from INSEAD in France.
- Catherine Owen Adams
Catherine Owen Adams，自2024年9月起担任首席执行官和董事会成员。此前，Owen Adams女士曾在全球生物制药公司Bristol Myers Squibb Company（“BMS”）担任高级副总裁兼美国区总经理，在那里她领导了一项价值200亿美元的商业业务，从2019年9月到2024年4月，她负责监督肿瘤学、心血管学和免疫学领域的大量多元化推广品牌组合。在这个角色中，她领导了超过3000名员工，并在肺癌、阻塞性肥厚型心肌病和银屑病领域推出了主要产品。在此之前，欧文·亚当斯女士曾担任BMS高级副总裁兼主要市场主管，在BMS与Celgene合并期间，她领导了商业运营，在欧洲、日本和加拿大的19个国家领导着6,000名员工。在她的领导下，她的团队在肿瘤学、CAR-T、血液学和免疫学领域实现了9个新产品发布，进一步巩固了她作为制药领域全球领导者的声誉。在任职于BMS之前，Owen Adams女士在强生（“强生”）工作了25年，在那里她在全球、美国和欧洲的业务部门担任领导职务，最后一个职位是杨森免疫学美国公司总裁。在强生的职业生涯中，她在制药和医疗技术领域的营销、销售、市场准入、研发以及内部企业方面积累了深厚的经验。目前，Owen Adams女士在公众持股公司Agios制药公司和私人持股公司AssistRX的董事会任职。Owen Adams女士以前是Optinose PLC的董事会成员和薪酬委员会主席，Optinose PLC是一家公共专业制药公司，并且是非营利组织Robert Wood Johnson University Hospitals的董事会成员。Owen Adams女士在获得曼彻斯特大学药学学士学位后，在阿斯利康开始了她的研发和制造职业生涯，成为一名合格的药剂师和皇家药学会（MRPHS）成员。
Catherine Owen Adams,has served as Chief Executive Officer and as a member of Board of Directors since September 2024. Previously, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb Company ("BMS"), a global biopharmaceutical company, where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology from September 2019 to April 2024. In this role, she led over 3,000 employees and major product launches in lung cancer, obstructive hypertrophic cardiomyopathy, and psoriasis. Before this, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Under her leadership her teams achieved 9 new product launches in Oncology, CAR-T, Hematology, and Immunology, further solidifying her reputation as a global leader in the pharmaceutical space. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson ("J&J"), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Over her career at J&J, she gained deep experience in marketing, sales, market access, R&D, and internal ventures across both the Pharmaceutical and Medical Technology sectors. Currently, Ms. Owen Adams serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca after earning a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).- Catherine Owen Adams，自2024年9月起担任首席执行官和董事会成员。此前，Owen Adams女士曾在全球生物制药公司Bristol Myers Squibb Company（“BMS”）担任高级副总裁兼美国区总经理，在那里她领导了一项价值200亿美元的商业业务，从2019年9月到2024年4月，她负责监督肿瘤学、心血管学和免疫学领域的大量多元化推广品牌组合。在这个角色中，她领导了超过3000名员工，并在肺癌、阻塞性肥厚型心肌病和银屑病领域推出了主要产品。在此之前，欧文·亚当斯女士曾担任BMS高级副总裁兼主要市场主管，在BMS与Celgene合并期间，她领导了商业运营，在欧洲、日本和加拿大的19个国家领导着6,000名员工。在她的领导下，她的团队在肿瘤学、CAR-T、血液学和免疫学领域实现了9个新产品发布，进一步巩固了她作为制药领域全球领导者的声誉。在任职于BMS之前，Owen Adams女士在强生（“强生”）工作了25年，在那里她在全球、美国和欧洲的业务部门担任领导职务，最后一个职位是杨森免疫学美国公司总裁。在强生的职业生涯中，她在制药和医疗技术领域的营销、销售、市场准入、研发以及内部企业方面积累了深厚的经验。目前，Owen Adams女士在公众持股公司Agios制药公司和私人持股公司AssistRX的董事会任职。Owen Adams女士以前是Optinose PLC的董事会成员和薪酬委员会主席，Optinose PLC是一家公共专业制药公司，并且是非营利组织Robert Wood Johnson University Hospitals的董事会成员。Owen Adams女士在获得曼彻斯特大学药学学士学位后，在阿斯利康开始了她的研发和制造职业生涯，成为一名合格的药剂师和皇家药学会（MRPHS）成员。
- Catherine Owen Adams,has served as Chief Executive Officer and as a member of Board of Directors since September 2024. Previously, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb Company ("BMS"), a global biopharmaceutical company, where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology from September 2019 to April 2024. In this role, she led over 3,000 employees and major product launches in lung cancer, obstructive hypertrophic cardiomyopathy, and psoriasis. Before this, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Under her leadership her teams achieved 9 new product launches in Oncology, CAR-T, Hematology, and Immunology, further solidifying her reputation as a global leader in the pharmaceutical space. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson ("J&J"), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Over her career at J&J, she gained deep experience in marketing, sales, market access, R&D, and internal ventures across both the Pharmaceutical and Medical Technology sectors. Currently, Ms. Owen Adams serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca after earning a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).
- Jennifer J. Rhodes
Jennifer J. Rhodes，她于2012年加入Medivation担任法律总顾问并于2012年7月被任命为首席合规官，于2013年4月被任命为企业秘书长。在2006年5月至2012年6月间，她在Pfizer Inc.担任助理企业秘书长长，支持了U.S. Primary Care Business及其Primary Care Medicines Development Group并担任Pfizer Inc.首要护理药物法定产品领导人。加入Pfizer Inc.之前，从2000年10月到2006年4月她在Weil, Gotshal & Manges, LLP工作，负责管理法和国际贸易业务领域。在1998年9月至2000年8月期间，她是美国国际贸易法庭（United States Court of International Trade）审判长Gregory A. Carman的助手。她从杜兰大学纽科姆学院（Newcomb College of Tulane University）获得经济学学士学位并从维克森林大学法学院（Wake Forest University School of Law）获得法学博士学位。
Jennifer J. Rhodes has been our Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020. In February 2019 Ms. Rhodes also became a director of Legal Aid at Work, a non-profit legal services organization. Ms. Rhodes previously served as General Counsel and Corporate Secretary at Adamas Pharmaceuticals, Inc., a public pharmaceutical company, from April 2016 until January 2020 during which time she also served as Chief Compliance Officer since August 2016 and Chief Business Officer since January 2017. Prior to that, Ms. Rhodes served as General Counsel at Medivation, Inc., a biopharmaceutical company, from June 2012 to September 2015 where she was responsible for Medivation's legal matters, and also served as Corporate Secretary from April 2013 to September 2015 and as Chief Compliance Officer from July 2012 to October 2014. From May 2006 to June 2012 Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., a biopharmaceutical company, where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group and served as a global product lead for Pfizer Inc.'s primary care medicines. Prior to joining Pfizer Inc., she was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Ms. Rhodes has a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.- Jennifer J. Rhodes，她于2012年加入Medivation担任法律总顾问并于2012年7月被任命为首席合规官，于2013年4月被任命为企业秘书长。在2006年5月至2012年6月间，她在Pfizer Inc.担任助理企业秘书长长，支持了U.S. Primary Care Business及其Primary Care Medicines Development Group并担任Pfizer Inc.首要护理药物法定产品领导人。加入Pfizer Inc.之前，从2000年10月到2006年4月她在Weil, Gotshal & Manges, LLP工作，负责管理法和国际贸易业务领域。在1998年9月至2000年8月期间，她是美国国际贸易法庭（United States Court of International Trade）审判长Gregory A. Carman的助手。她从杜兰大学纽科姆学院（Newcomb College of Tulane University）获得经济学学士学位并从维克森林大学法学院（Wake Forest University School of Law）获得法学博士学位。
- Jennifer J. Rhodes has been our Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020. In February 2019 Ms. Rhodes also became a director of Legal Aid at Work, a non-profit legal services organization. Ms. Rhodes previously served as General Counsel and Corporate Secretary at Adamas Pharmaceuticals, Inc., a public pharmaceutical company, from April 2016 until January 2020 during which time she also served as Chief Compliance Officer since August 2016 and Chief Business Officer since January 2017. Prior to that, Ms. Rhodes served as General Counsel at Medivation, Inc., a biopharmaceutical company, from June 2012 to September 2015 where she was responsible for Medivation's legal matters, and also served as Corporate Secretary from April 2013 to September 2015 and as Chief Compliance Officer from July 2012 to October 2014. From May 2006 to June 2012 Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., a biopharmaceutical company, where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group and served as a global product lead for Pfizer Inc.'s primary care medicines. Prior to joining Pfizer Inc., she was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Ms. Rhodes has a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.